纳尔布芬片用于治疗异常性肺纤维化患者的咳
Toby M Maher1,2, Cristina Avram3, Enoch Bortey4
1Keck School of Medicine, University of Southern California, Los Angeles.
NEJM evidence
|February 6, 2024
概括
纳尔布芬延长释放剂 (NAL ER) 在异常性肺纤维化 (IPF) 患者中显著减少了咳. 这项研究表明,NAL ER作为IPF相关咳的有希望的治疗方法,尽管需要进一步的研究.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 目前,异形性肺纤维化 (IPF) 缺乏用于相关慢性咳的批准疗法.
- 研究新型治疗剂对于管理IPF患者的衰弱症状至关重要.
研究的目的:
- 评估纳尔布芬延长释放片 (NAL ER) 降低IPF患者咳频率的疗效.
- 在这个患者群体中评估NAL ER的安全性和耐受性.
主要方法:
- 一项随机,双盲,安慰剂控制的交叉试验与41名IPF患者进行.
- 参与者接受了NAL ER或安慰剂两次22天的时间,两周的洗.
- NAL ER的剂量定位从每天一次的27毫克到每天两次的162毫克不等.
主要成果:
- 在NAL ER中,白天客观咳频率减少了52.5个百分点 (调整为安慰剂),减少了75.1%.
- 在24小时客观咳频率与NAL ER (76.1%的下降) 中,观察到与安慰剂调整后的50.8个百分点的变化.
- 与安慰剂相比,NAL ER的不良事件包括恶心,疲劳,便秘和头更频繁.
结论:
- 短期使用NAL ER有效地减少了IPF患者的咳.
- 需要进行更大规模,更长期的研究,以全面评估NAL ER对IPF相关咳的风险益处概况.
更多相关视频
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
287
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
287
Pulmonary Tuberculosis V
180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
COPD: Management Using Bronchodilators and Corticosteroids
207
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
207
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Inhaled Medications
269
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
269


